SCHEMBL692614

SCHEMBL692614

Cc1cc(=O)n(-c2ccc(O)c(C(=O)O)c2)[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.64
▸ MAPT P10636 3/20 0.64
▸ KDM4E B2RXH2 3/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ GAA P10253 2/20 0.60
▸ HTT P42858 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ PKM P14618 1/20 0.55
▸ ALKBH5 Q6P6C2 8/20 0.50
▸ LMNA P02545 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ CSNK2A1 P68400 1/20 0.47
▸ KDM5A P29375 1/20 0.47
▸ KDM2B Q8NHM5 1/20 0.47
▸ KDM4C Q9H3R0 1/20 0.47
▸ MYC P01106 2/20 0.46
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11589085 0.88 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL11586022 0.84 MAPT (0.62) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL394287 0.78 ALDH1A1 (1.00) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL692943 0.75 ALDH1A1 (0.59) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL7894742 0.75 ALDH1A1 (0.70) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
Anthranilic Acid SCHEMBL10820844 0.73 MAPT (0.59) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL11435207 0.73 ALDH1A1 (0.60) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL407942 0.73 ALKBH5 (0.64) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
Methyl Alcohol SCHEMBL1028813 0.73 MAPT (0.69) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL9150171 0.72 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421613-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF The Procter & Gamble Company (US) 2012-02-29 — — EP claimed
US-7985266-B2 Keratin dyeing compositions comprising a radical scavenger and a chelant and use thereof THE PROCTER & GAMBLE COMPANY (US) 2011-07-26 — — US claimed
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof NOXELL CORPORATION 2011-02-17 — — US claimed
WO-2010123866-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2010-10-28 — — WO claimed
EP-2421613-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF The Procter & Gamble Company (US) 2012-02-29 — — EP disclosed
US-7985266-B2 Keratin dyeing compositions comprising a radical scavenger and a chelant and use thereof THE PROCTER & GAMBLE COMPANY (US) 2011-07-26 — — US disclosed
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof NOXELL CORPORATION 2011-02-17 — — US disclosed
WO-2010123866-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof KRT18, LPO, KRTCAP2 ALDH1A1 354/4885MAPT 547/4885KDM4E 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback